Dube; Laurence

Patent Applications and Registrations

Patent applications and USPTO patent grants for Dube; Laurence.The latest application filed is for "imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (par4) inhibitors for treating platelet aggre".

Company Profile

3.10.11

Dube; Laurence - Laval CA
Dube; Laurence - Lava CA
Dube; Laurence - Ste-Dorothee CA
Dube; Laurence - Pierrefonds CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation Grant 10,822,343 - Banville , et al. November 3, 2	2020-11-03
Imidazothiadiazole And Imidazopyrazine Derivatives As Protease Activated Receptor4 (par4) Inhibitors For Treating Platelet Aggre App 20200123160 - Banville; Jacques ; et al.	2020-04-23
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation Grant 10,428,077 - Banville , et al. October 1, 2	2019-10-01
Imidazothiadiazole And Imidazopyrazine Derivatives As Protease Activated Receptor4 (par4) Inhibitors For Treating Platelet Aggregation App 20180305376 - Banville; Jacques ; et al.	2018-10-25
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation Grant 10,047,103 - Banville , et al. August 14, 2	2018-08-14
Imidazothiadiazole And Imidazopyrazine Derivatives As Protease Activated Receptor4 (par4) Inhibitors For Treating Platelet Aggregation App 20170247395 - Banville; Jaques ; et al.	2017-08-31
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation Grant 9,688,695 - Banville , et al. June 27, 2	2017-06-27
Imidazothiadiazole And Imidazopyrazine Derivatives As Protease Activated Receptor 4 (par4) Inhibitors For Treating Platelet Aggregation App 20150094297 - Banville; Jacques ; et al.	2015-04-02
Renin Inhibitors App 20120046293 - BAYLY; CHRISTOPHER I. ; et al.	2012-02-23
Renin inhibitors Grant 8,063,105 - Bayly , et al. November 22, 2	2011-11-22
Renin Inhibitors App 20090281103 - Bayly; Christopher I. ; et al.	2009-11-12
8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors Grant 7,482,456 - Dube , et al. January 27, 2	2009-01-27
4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors Grant 7,342,024 - Dube , et al. March 11, 2	2008-03-11
4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors Grant 7,238,706 - Dube , et al. July 3, 2	2007-07-03
8-(biaryl)quinoline PDE4 inhibitors Grant 7,153,968 - Dube , et al. December 26, 2	2006-12-26
Hetero-bridge substituted 8-arylquinoline pde4 inhibitors Grant 7,144,896 - Gallant , et al. December 5, 2	2006-12-05
8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors App 20060223850 - Dube; Daniel ; et al.	2006-10-05
4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors App 20060058316 - Dube; Daniel ; et al.	2006-03-16
Hetero-bridge substituted 8-arylquinoline pde4 inhibitors App 20050245513 - Gallant, Michel ; et al.	2005-11-03
8-(Biaryl)quinoline pde4 inhibitors App 20050234238 - Dube, Daniel ; et al.	2005-10-20
4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors App 20050107402 - Dube, Daniel ; et al.	2005-05-19

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.